Article

Nivolumab May Soon Be Approved as First-Line in Advanced Melanoma

A press release by Bristol-Myers Squibb announced their filing of a supplemental Biologics License Application for Opdivo (nivolumab) in the treatment of previously untreated individuals with advanced melanoma.

Bristol-Myers Squibb Company today announced that the FDA has accepted for filing and review the supplemental Biologics License Application for Opdivo (nivolumab) for the treatment of previously untreated patients with unresectable or metastatic melanoma. The FDA also granted Priority Review for this application. The projected FDA action date is August 27, 2015.

Opdivo was first approved by the FDA in December 2014 for patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilimumab) and, if BRAF V600 mutation positive, a BRAF inhibitor.

Read the complete press release by BMS: http://on.mktw.net/1AkL8w8

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
4 experts in this video
4 experts in this video
Dr Caroline Vovan
1 expert is featured in this series.
1 expert is featured in this series.
Dr María Díez Campelo
Dr Caroline Vovan
Guy Young, MD
Dr Hans Lee
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo